Finoriq research workspace
Akebia Therapeutics, Inc. (AKBA) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Akebia Therapeutics, Inc. (AKBA).
Company Snapshot
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Company
- Akebia Therapeutics, Inc. (AKBA)
- Ticker
- AKBA
- Market Cap
- $342M
- Latest Price
- $1.275
- Industry
- Biotech & Pharma
Akebia Therapeutics, Inc. (AKBA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Akebia Therapeutics, Inc. (AKBA).
| Event | Form | Date |
|---|---|---|
| Akebia Therapeutics, Inc.: Corporate updateOn June 30, 2026, the Company and USRC announced the results of a planned interim analysis of the VOICE trial and that it met the predefine... | 8-K8.01 | 2026-06-30 |
| On June 30, 2026, Akebia Therapeutics, Inc. and U.S. Renal Care issued a press release announci...On June 30, 2026, Akebia Therapeutics, Inc. (the "Company") and U.S. Renal Care ("USRC) issued a press release announcing the results of a... | 8-K7.01 | 2026-06-30 |
| Akebia Therapeutics, Inc.: Shareholder voteOn June 17, 2026, Akebia Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider... | 8-K5.07 | 2026-06-22 |
| Akebia Therapeutics, Inc.: Earnings or resultsOn May 7, 2026, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter end... | 8-K2.02 | 2026-05-07 |
| Washington, D.C. 20549Date of Report (Date of earliest event reported): March 27, 2026 | 8-K5.02 | 2026-04-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.